PDL BioPharma (PDLI) Adds Bruce Tomlinson as CFO
Tweet Send to a FriendGet Alerts PDLI Hot Sheet
Price: $7.92 +2.33%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 7.6%
Revenue Growth %: -7.0%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 7.6%
Revenue Growth %: -7.0%
Trade PDLI Now!
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) has appointed Bruce Tomlinson to the position of vice president and chief financial officer effective as of June 11, 2012. Mr. Tomlinson brings more than 20 years of financial leadership experience to PDL and joins the company from the biopharmaceutical company InterMune, Inc.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- John Wiley (JW-A) Misses Q4 EPS by 9c; Names New CFO; Updates on Restructuring
- HP's (HPQ) Decision to Get Rid of Todd Bradley Is a Positive - Analyst
- PDL BioPharma (PDLI) Issues Strong Prelim. Q2 Royalty Revs Outlook
Create E-mail Alert Related Categories
Management Changes
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
